The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Therapeutics, Inc. COM 00461U105 372 144,874 SH   SOLE   144,874 0 0
ALX Oncology Holdings Inc. COM 00166B105 36,740 973,514 SH   SOLE   973,514 0 0
Arbutus Biopharma Corp COM 03879J100 10,431 3,332,616 SH   SOLE   3,332,616 0 0
Cymabay Therapeutics, Inc. COM 23257D103 12,939 1,787,094 SH   SOLE   1,787,094 0 0
Cytokinetics Incorporated COM 23282W605 36,205 1,672,292 SH   SOLE   1,672,292 0 0
Generation Bio Co. COM 37148K100 26,519 857,939 SH   SOLE   857,939 0 0
Keros Therapeutics, Inc. COM 492327101 54,488 1,412,705 SH   SOLE   1,412,705 0 0
Kura Oncology, Inc. COM 50127T109 40,077 1,307,982 SH   SOLE   1,307,982 0 0
Myokardia, Inc. COM 62857M105 17,245 126,492 SH   SOLE   126,492 0 0
Nurix Therapeutics, Inc. COM 67080M103 81,969 2,348,014 SH   SOLE   2,348,014 0 0
Panacea Acquisition Corp UNIT 698102209 1,800 150,000 SH   SOLE   150,000 0 0
Relay Therapeutics, Inc. COM 75943R102 91,116 2,139,380 SH   SOLE   2,139,380 0 0
Therapeutics Acquisition Corp COM CL A 88339T103 5,033 350,000 SH   SOLE   350,000 0 0
Vaxcyte, Inc. COM 92243G108 23,002 465,821 SH   SOLE   465,821 0 0
Voyager Therapeutics, Inc. COM 92915B106 5,514 516,751 SH   SOLE   516,751 0 0